GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » Cyclically Adjusted PB Ratio

Amarin (Amarin) Cyclically Adjusted PB Ratio : 1.56 (As of Apr. 28, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Amarin Cyclically Adjusted PB Ratio?

As of today (2024-04-28), Amarin's current share price is $0.8749. Amarin's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $0.56. Amarin's Cyclically Adjusted PB Ratio for today is 1.56.

The historical rank and industry rank for Amarin's Cyclically Adjusted PB Ratio or its related term are showing as below:

AMRN' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.48   Med: 3.05   Max: 324
Current: 1.56

During the past years, Amarin's highest Cyclically Adjusted PB Ratio was 324.00. The lowest was 0.48. And the median was 3.05.

AMRN's Cyclically Adjusted PB Ratio is ranked better than
55.49% of 647 companies
in the Drug Manufacturers industry
Industry Median: 1.75 vs AMRN: 1.56

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Amarin's adjusted book value per share data for the three months ended in Dec. 2023 was $1.350. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.56 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Amarin Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Amarin's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amarin Cyclically Adjusted PB Ratio Chart

Amarin Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 17.73 3.29 1.55

Amarin Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.29 3.55 2.46 1.75 1.55

Competitive Comparison of Amarin's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - General subindustry, Amarin's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Amarin's Cyclically Adjusted PB Ratio falls into.



Amarin Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Amarin's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.8749/0.56
=1.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amarin's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Amarin's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=1.35/120.1096*120.1096
=1.350

Current CPI (Dec. 2023) = 120.1096.

Amarin Quarterly Data

Book Value per Share CPI Adj_Book
201403 -0.333 100.573 -0.398
201406 -0.289 100.773 -0.344
201409 -0.397 100.474 -0.475
201412 -0.507 99.576 -0.612
201503 -0.497 99.975 -0.597
201506 -0.615 100.573 -0.734
201509 -0.739 100.274 -0.885
201512 -0.828 99.676 -0.998
201603 -0.979 99.676 -1.180
201606 -1.023 101.072 -1.216
201609 -0.034 100.274 -0.041
201612 -0.124 99.676 -0.149
201703 -0.196 100.374 -0.235
201706 -0.233 100.673 -0.278
201709 -0.260 100.474 -0.311
201712 -0.330 100.075 -0.396
201803 -0.140 100.573 -0.167
201806 -0.242 101.072 -0.288
201809 -0.246 101.371 -0.291
201812 0.400 100.773 0.477
201903 0.360 101.670 0.425
201906 0.384 102.168 0.451
201909 1.606 102.268 1.886
201912 1.628 102.068 1.916
202003 1.559 102.367 1.829
202006 1.544 101.769 1.822
202009 1.548 101.072 1.840
202012 1.599 101.072 1.900
202103 1.608 102.367 1.887
202106 1.633 103.364 1.898
202109 1.624 104.859 1.860
202112 1.682 106.653 1.894
202203 1.615 109.245 1.776
202206 1.460 112.734 1.556
202209 1.456 113.431 1.542
202212 1.472 115.425 1.532
202303 1.436 117.618 1.466
202306 1.394 119.611 1.400
202309 1.354 120.708 1.347
202312 1.350 120.110 1.350

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Amarin  (NAS:AMRN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Amarin Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Amarin's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3